Lumos Labs launches the Lumosity Research Platform, combining cognitive assessments, digital cognitive training interventions, participant recruitment, and real-world data in one platform for cognitive research.
Lumosity announces that the U.S. Food and Drug Administration (FDA) grants 510(k) clearance for LumosityRx, a prescription digital therapeutic designed to improve attention in adults with attention deficit hyperactivity disorder (ADHD). The product is intended for adults ages 22 to 55.
Lumos Labs and psychologist Allen Osman, PhD, lead a big-data study using Lumosity gameplay to examine cognitive training and cognitive performance. The study reports a clear link between the amount of brain training and improvements in cognition across all ages.
Lumos Labs appoints neuroscientist Bob Schafer, PhD, as chief executive officer as it expands into digital medicine. The company makes Lumosity brain training and describes itself as a leader in digital health for the brain and cognition.
